Solubilizing Mutations Used to Crystallize One CFTR Domain Attenuate the Trafficking and Channel Defects Caused by the Major Cystic Fibrosis Mutation

Chemistry and Biology

Volumn 15, Issue 1, 2008, Pages 62-69

  Pissarra, Luísa S ^a   Farinha, Carlos M ^a,b   Xu, Zhe ^c   Schmidt, André ^b   Thibodeau, Patrick H ^d   Cai, Zhiwei ^c   Thomas, Philip J ^d   Sheppard, David N ^c   Amaral, Margarida D ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CELLBIO; CHEMBIO

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; NUCLEOTIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHEMISTRY; CRYSTALLIZATION; CYSTIC FIBROSIS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROTEIN CONFORMATION; SOLUBILITY; STEREOISOMERISM; TIME; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MUTATION; NUCLEOTIDES; PROTEIN CONFORMATION; SOLUBILITY; STEREOISOMERISM; TIME FACTORS;

EID: 38349050413     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2007.11.012     Document Type: Article

References (41)

1. Bianchet M.A., Ko Y.H., Amzel L.M., and Pedersen P.L. Modeling of nucleotide binding domains of ABC transporter proteins based on a F1-ATPase/recA topology: structural model of the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR). J. Bioenerg. Biomembr. 29 (1997) 503-524
2. Brown C.R., Hong-Brown L.Q., Biwersi J., Verkman A.S., and Welch W.J. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1 (1996) 117-125
3. - channel. J. Biol. Chem. 281 (2006) 1970-1977
4. - channel. In: Pusch M. (Ed). Chloride Movements across Cellular Membranes (2007), Elsevier Limited, San Diego 109-143
5. 2-terminal nucleotide binding domain. J. Gen. Physiol. 116 (2000) 163-180
6. Chang X.B., Hou Y.X., Jensen T.J., and Riordan J.R. Mapping of cystic fibrosis transmembrane conductance regulator membrane topology by glycosylation site insertion. J. Biol. Chem. 269 (1994) 18572-18575
7. Chang X.B., Cui L., Hou Y.X., Jensen T.J., Aleksandrov A.A., Mengos A., and Riordan J.R. Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. Mol. Cell 4 (1999) 137-142
8. Chen E.Y., Bartlett M.C., Loo T.W., and Clarke D.M. The deltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 279 (2004) 39620-39627
9. Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A., O'Riordan C.R., and Smith A.E. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990) 827-834
10. Cheng S.H., Fang S.L., Zabner J., Marshall J., Piraino S., Schiavi S.C., Jefferson D.M., Welsh M.J., and Smith A.E. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am. J. Physiol. 268 (1995) L615-L624
11. Cui L., Aleksandrov L., Hou Y.X., Gentzsch M., Chen J.H., Riordan J.R., and Aleksandrov A.A. The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. J. Physiol. 572 (2006) 347-358
12. deCarvalho A.C.V., Gansheroff L.J., and Teem J.L. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta F508. J. Biol. Chem. 277 (2002) 35896-35905
13. Denning G.M., Anderson M.P., Amara J.F., Marshall J., Smith A.E., and Welsh M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358 (1992) 761-764
14. Dörk T., Wulbrand U., Richter T., Neumann T., Wolfes H., Wulf B., Maass G., and Tümmler B. Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Hum. Genet. 87 (1991) 441-446
15. Du K., Sharma M., and Lukacs G.L. The deltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12 (2005) 17-25
16. Dulhanty A.M., and Riordan J.R. A two-domain model for the R domain of the cystic fibrosis transmembrane conductance regulator based on sequence similarities. FEBS Lett. 343 (1994) 109-114
17. Farinha C.M., and Amaral M.D. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol. Cell. Biol. 25 (2005) 5242-5252
18. Farinha C.M., Mendes F., Roxo-Rosa M., Penque D., and Amaral M.D. A comparison of 14 antibodies for the biochemical detection of the cystic fibrosis transmembrane conductance regulator protein. Mol. Cell. Probes 18 (2004) 235-242
19. Farinha C.M., Penque D., Roxo-Rosa M., Lukacs G., Dormer R., McPherson M., Pereira M., Bot A.G., Jorna H., Willemsen R., et al. Biochemical methods to assess CFTR expression and membrane localization. J. Cyst. Fibros. 3 Suppl 2 (2004) 73-77
20. Hammerle M.M., Aleksandrov A.A., Chang X.B., and Riordan J.R. A novel CFTR disease-associated mutation causes addition of an extra N-linked oligosaccharide. Glycoconj. J. 17 (2000) 807-813
21. Hollenstein K., Dawson R.J., and Locher K.P. Structure and mechanism of ABC transporter proteins. Curr. Opin. Struct. Biol. 17 (2007) 412-418
22. Jensen T.J., Loo M.A., Pind S., Williams D.B., Goldberg A.L., and Riordan J.R. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83 (1995) 129-135
23. - channels expressed in mammalian cells. J. Physiol. 508 (1998) 379-392
24. Lewis H. Structures of human CFTR NBD1 confirm conservation of the domain structure despite the delF508 mutation. Pediatr. Pulmonol. 40 (2005) 190-191
25. Lewis H.A., Buchanan S.G., Burley S.K., Conners K., Dickey M., Dorwart M., Fowler R., Gao X., Guggino W.B., Hendrickson W.A., et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 23 (2004) 282-293
26. Lewis H.A., Zhao X., Wang C., Sauder J.M., Rooney I., Noland B.W., Lorimer D., Kearins M.C., Conners K., Condon B., et al. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J. Biol. Chem. 280 (2005) 1346-1353
27. Massiah M.A., Ko Y.H., Pedersen P.L., and Mildvan A.S. Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing deltaF508 mutation. Biochemistry 38 (1999) 7453-7461
28. Moran O., and Zegarra-Moran O. A quantitative description of the activation and inhibition of CFTR by potentiators: genistein. FEBS Lett. 579 (2005) 3979-3983
29. Ostedgaard L.S., Baldursson O., Vermeer D.W., Welsh M.J., and Robertson A.D. A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution. Proc. Natl. Acad. Sci. USA 97 (2000) 5657-5662
30. Qu B.H., and Thomas P.J. Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. J. Biol. Chem. 271 (1996) 7261-7264
31. Riordan J.R. Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67 (2005) 701-718
32. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., and Chou J.L. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989) 1066-1073
33. Rowe S.M., Miller S., and Sorscher E.J. Cystic fibrosis. N. Engl. J. Med. 352 (2005) 1992-2001
34. Roxo-Rosa M., Xu Z., Schmidt A., Neto M., Cai Z., Soares C.M., Sheppard D.N., and Amaral M.D. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc. Natl. Acad. Sci. USA 103 (2006) 17891-17896
35. Schmidt A., Hughes L.K., Cai Z., Mendes F., Li H., Sheppard D.N., and Amaral M.D. Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br. J. Pharmacol. (2008) in press
36. Teem J.L., Berger H.A., Ostedgaard L.S., Rich D.P., Tsui L.C., and Welsh M.J. Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast. Cell 73 (1993) 335-346
37. Teem J.L., Carson M.R., and Welsh M.J. Mutation of R555 in CFTR-delta F508 enhances function and partially corrects defective processing. Receptors Channels 4 (1996) 63-72
38. Thibodeau P.H., Brautigam C.A., Machius M., and Thomas P.J. Side chain and backbone contributions of Phe508 to CFTR folding. Nat. Struct. Mol. Biol. 12 (2005) 10-16
39. Vashist S., and Ng D.T. Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. J. Cell Biol. 165 (2004) 41-52
40. Vergani P., Lockless S.W., Nairn A.C., and Gadsby D.C. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433 (2005) 876-880
41. Ward C.L., Omura S., and Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83 (1995) 121-127